Background Carbidopa/levodopa enteral suspension (CLES) is indicated for the treatment of advanced Parkinson''s disease (aPD) with severe motor fluctuations. Objective To determine the cost, quality‐adjusted life years (QALY), and cost‐effectiveness of CLES compared to the standard‐of‐care (...
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK Evaluation of cost-effectiveness of levodopa/carbidopa intestinal gel (LCIG), compared to standard care (SC) in patients with advanced Parkinson's disease ... ...
levodopa/carbidopa intestinal gelBackground: Parkinson's disease (PD) is an incurable, progressive neurological condition, with symptoms impacting movement, walking, and posture that eventually become severely disabling. Advanced PD (aPD) has a significant impact on quality-of-life (QoL) for patients...
This study evaluated the effectiveness of carbidopa/levodopa enteral suspension (CLES) and deep brain stimulation (DBS) on reducing pill burden in APD patients. Methods:We utilized 100% Medicarefee-for-service claims from 2014 to 2018 linked to CLES Patient Support Program (PSP) data. CLES ...
Introduction: In advanced Parkinson's disease (PD), a high pill burden is associated with poor compliance, reduced control of symptoms, and decreased quality of life. We assessed the impact of carbidopa鈥搇evodopa enteral suspension (CLES) and deep brain stimulation (DBS) on P...
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005; 21: 1005-14.Findley LJ, Lees A, Apajasalo M, Pitkanen A, Turunen H. Cost-effectiveness of levodopa/carbidopa/entacapone (...
Background and methods: A Markov model was developed to evaluate the cost-effectiveness of levodopa/carbidopa/entacapone (LCE;Stalevo*), in the treatment of patients with Parkinson''s disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other antiparkinsonian ...
Levodopa-carbidopa intestinal gelParkinson's diseaseBackground: Treatment with levodopa-carbidopa intestinal gel (LCIG) can effectively relieve motor and non-motor symptoms in advanced Parkinson's disease (PD). However, adverse events (AEs) are frequent. Objective: To describe AEs associated with LCIG...
Levodopa-carbidopa intestinal gelMotor symptomsNon-motor symptomsQuality of lifeRoutine patient careLCIG improved motor fluctuations, non-motor symptoms and quality of life over 24months while tolerability was consistent with the established safety profile....
Evaluation of cost-effectiveness of levodopa/carbidopa intestinal gel (LCIG), compared to standard care (SC) in patients with advanced Parkinson's disease (aPD) in the UK.Markov model to quantify costs and outcomes associated with LCIG versus SC in aPD patients at Hoehn and Yahr (H&Y) stages...